Healthcare Stocks Stable Amid Broad Markets Rise — Healthcare Roundup

Healthcare stocks remained flat despite a broader market rise. Johnson & Johnson raised full-year guidance on strong Q2 earnings driven by oncology, offsetting Stelara sales declines. Elevance Health fell 9% despite beating earnings estimates and raising its outlook. Boehringer Ingelheim reported increased H1 sales for Jardiance as it prepares to file for U.S. approval of a new obesity medicine.

Stocks in the healthcare sector were flat amid a broader stock market rise.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara.

Elevance Health fell 9% although the health insurer beat earnings estimates and boosted its full-year outlook for the second time in months.

Boehringer Ingelheim said its Jardiance diabetes drug helped it increase sales in the first half, as the German drugmaker gears up to file for U.S. approval of a new obesity medicine.

Write to Paulo Trevisani at paulo.trevisani@wsj.com

(END) Dow Jones Newswires

July 15, 2026 18:14 ET (22:14 GMT)